PHILADELPHIA, Dec. 22, 2020 (GLOBE NEWSWIRE) —
Kaskela Law LLC announces that it is investigating NantKwest, Inc. (“NantKwest”) (NASDAQ: NK) on behalf of the company’s shareholders.
NantKwest shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 – 1585, or by email at firstname.lastname@example.org or online at https://kaskelalaw.com/case/nantkwest-inc/, for additional information about this investigation and their legal rights and options.
On December 21, 2020, NantKwest announced that it had entered into an agreement to merge with ImmunityBio, a privately-held company, in a stock-for-stock transaction. Following the closing of the transaction, NantKwest shareholders will only own approximately 28% of the combined company.
The investigation seeks to determine whether the transaction as structured is fair to NantKwest shareholders, and whether NantKwest’s officers and/or directors breached their fiduciary duties in connection with the agreement.
Kaskela Law LLC represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.
D. Seamus Kaskela, Esq.
KASKELA LAW LLC
18 Campus Boulevard, Suite 100
Newtown Square, PA 19073
(484) 258 – 1585
This notice may constitute attorney advertising in certain jurisdictions.
- From 2023 through 2033, The qPCR Instruments Market is Expected to Reach US$ 1.8 Billion, Reveals Future Market Insights, Inc. - February 5, 2023
- Shrimp Industry is likely to Reach US$ 123.8 billion by 2033 Says Future Market Insights, Inc. - February 5, 2023
- FBLA Week Celebrates Organization’s Mission and Impact - February 5, 2023